作者
Xiaoxia Zhou,Zhenhua Liu,Xiaoting Zhou,Yaqin Xiang,Zhou Zhou,Yuwen Zhao,Hongxu Pan,Qian Xu,Yase Chen,Qiying Sun,Xinyin Wu,Hongzhuan Tan,Bin Li,Kai Yuan,Yali Xie,Weihua Liao,Shuo Hu,Jianping Zhu,Xuehong Wu,Jianhua Li,Chunyu Wang,Lifang Lei,Jiayu Tang,Yonghong Liu,Heng Wu,Wei Huang,Tao Wang,Zheng Xue,Puqing Wang,Zhentao Zhang,Ping Xu,Ling Chen,Qing Wang,Xuejing Wang,Oumei Cheng,Yuefei Shen,Weiguo Liu,Min Ye,Yong You,Jinchen Li,Xinxiang Yan,Jifeng Guo,Beisha Tang
摘要
Abstract Background There is a lack of large multicenter Parkinson's disease (PD) cohort studies and limited data on the natural history of PD in China. Objectives The objective of this study was to launch the Chinese Parkinson's Disease Registry (CPDR) and to report its protocol, cross‐sectional baseline data, and prospects for a comprehensive observational, longitudinal, multicenter study. Methods The CPDR recruited PD patients from 19 clinical sites across China between January 2018 and December 2020. Clinical data were collected prospectively using at least 17 core assessment scales. Patients were followed up for clinical outcomes through face‐to‐face interviews biennially. Results We launched the CPDR in China based on the Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network (PD‐MDCNC). A total of 3148 PD patients were enrolled comprising 1623 men (51.6%) and 1525 women (48.4%). The proportions of early‐onset PD (EOPD, age at onset ≤50 years) and late‐onset PD (LOPD) were 897 (28.5%) and 2251 (71.5%), respectively. Stratification by age at onset showed that EOPD manifested milder motor and nonmotor phenotypes and was related to increased probability of dyskinesia. Comparison across genders suggested a slightly older average age at PD onset, milder motor symptoms, and a higher rate of developing levodopa‐induced dyskinesias in women. Conclusions The CPDR is one of the largest multicenter, observational, longitudinal, and natural history studies of PD in China. It offers an opportunity to expand the understanding of clinical features, genetic, imaging, and biological markers of PD progression. © 2022 International Parkinson and Movement Disorder Society.